Go to the profile of Fate Therapeutics

Fate Therapeutics

 
  • 858.875.1800
  • Networkers
  • United States of America
NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
Go to the profile of Teddy Wijaya
Teddy Wijaya

Technology enthusiast, self

Founded in London (United Kingdom) in 2016, MicroQuin was born out of a collaborative and inclusive approach to research. MicroQuin is a biotechnology, R&D based company currently focusing on developing therapeutics to address a range of oncological disease. MicroQuin is progressing lead compounds into clinical trials, which offer a potential cure to Breast Cancer and other diseases.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature

Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Go to the profile of Veronica Zacatenco
Veronica Zacatenco

Business Development Executive, Nature Publishing Group

Our team makes every effort to support the business development needs of the biopartnering community through our publications BioPharma Dealmakers, MedTech Dealmakers and our series of associated webcasts. I am interested in hearing about your partnering communication needs as well as your suggestions or comments.